AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01943435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar epidural injection
Description: The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
Study NCT01943435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilizations (spine, sacroiliac, hip)
Description: These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
Study NCT01943435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized exercises: clinical setting
Description: The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
Study NCT01943435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise: community setting
Description: The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
Study NCT04026048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Insomnia (CBT-I)
Description: CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Study NCT03821415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution
Study NCT02108535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver
Description: Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
Study NCT02108535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
Study NCT03821415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RP101
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution
Study NCT01356030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
Study NCT01356030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA
Description: Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
Study NCT04266171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet education based on CGMS data
Description: Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
Study NCT04266171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diet education
Description: Control group will receive conventional diabetes diet education without CGMS data.
Study NCT00783120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
Study NCT00783120 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
Study NCT02911337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
Study NCT03230864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 10 mg/day, encapsulated tablets, orally
Study NCT03230864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally
Study NCT03230864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally
Study NCT01023334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSICS under topical anesthesia with intracameral lidocaine
Description: manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
Study NCT01023334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSICS under topical anesthesia with intracameral balanced salt solution.
Description: manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
Study NCT02524054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Study NCT02524054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized saline
Description: 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Study NCT01461785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Addition of PRP ( platelet rich plasma) to the lipograft
Description: 27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP
Study NCT01461785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipofilling of the midface
Description: The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
Study NCT01461785 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lipofilling of the midface
Description: The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
Study NCT00147134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open colectomy
Description: Procedure/Surgery: open colectomy
Study NCT00147134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic colectomy
Description: Procedure/Surgery: laparoscopic colectomy
Study NCT01354886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Description: single dose
Study NCT01354886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f
Description: 150 IU single dose
Study NCT01354886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bravelle
Description: 150 IU single dose
Study NCT01354886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study NCT00845637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eggplant extract
Description: Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
Study NCT00845637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
Study NCT00822744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: capsule~Route: oral administration with food
Study NCT00822744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food
Study NCT00822744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SSR411298)
Description: Form: capsule~Route: oral administration with food
Study NCT01802112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrins
Description: 15 grams of Resistant maltodextrins per day dissolved in water during 21 days
Study NCT01802112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 15gr placebo
Study NCT03389113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
Study NCT03389113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exersice
Description: Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
Study NCT03389113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exersice
Description: Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
Study NCT04046705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic matched related haematopoietic stem cell transplantation
Description: Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
Study NCT04046705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard arm
Description: In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
Study NCT00452348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Study NCT00452348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg BID
Description: Fluticasone propionate 250 mcg BID
Study NCT03577535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin®
Description: Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
Study NCT02466490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan tablets
Study NCT02466490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan tablets
Study NCT02466490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan; Hydrochlorothiazide
Description: Fimasartan plus hydrochlorothiazide fixed dose combination tablets
Study NCT02466490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan; Hydrochlorothiazide
Description: Fimasartan plus hydrochlorothiazide fixed dose combination tablets
Study NCT03769428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
Study NCT03769428 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham erector spinae plane block
Description: The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
Study NCT04224753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00027
Description: Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
Study NCT03314376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression.
Study NCT03922555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
Study NCT01250730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
Study NCT01250730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
Study NCT01250730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
Study NCT03051945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
Study NCT03051945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT02463981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)
Study NCT02463981 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)
Study NCT03044210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic evaluation
Description: * diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)
Study NCT03632031 — intervention group
Intervention type: DEVICE
Intervention: Oasis Extracellular Matrix
Description: Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
Study NCT00911274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 250 mg Capsule
Study NCT00911274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept®
Description: 250 mg Capsule
Study NCT01398475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study NCT03056430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study NCT00432679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (BRL49653C)
Description: study drug
Study NCT03709095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Description: Participants utilized the arm ergometer for improving aerobic exercise capacity
Study NCT03709095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continuous training
Description: Participants utilized the arm ergometer for improving aerobic exercise capacity
Study NCT01943825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT01943825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine
Description: 0.5 mL, Intramuscular
Study NCT00997412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: 180 mg/tablet, 4 tablets twice daily
Study NCT00997412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZA
Description: 1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
Study NCT03248466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG combined with BMMSCs transplantation
Description: PRG combined with BMMSCs transplantation
Study NCT03248466 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRG combined with BMMSCs transplantation
Description: PRG combined with BMMSCs transplantation
Study NCT01720602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT01388010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Fermented Probiotic Dairy Product (test)
Study NCT01388010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2-Milk-based non-fermented dairy product(control)
Study NCT01720602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT01720602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO